Agios PharmaceuticalsAGIO
About: Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Employees: 488
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 3 (+2) [Q1 2025]
0.25% less ownership
Funds ownership: 104.91% [Q4 2024] → 104.66% (-0.25%) [Q1 2025]
4% less call options, than puts
Call options by funds: $10.6M | Put options by funds: $11.1M
5% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 77
8% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 40
3% less funds holding
Funds holding: 223 [Q4 2024] → 217 (-6) [Q1 2025]
11% less capital invested
Capital invested by funds: $1.97B [Q4 2024] → $1.76B (-$207M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Scotiabank Greg Harrison | 82%upside $71 | Sector Outperform Maintained | 2 May 2025 |
Financial journalist opinion
